XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Shareholders’ Deficit (Details) - $ / shares
 3 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Jul. 27, 2023
Mar. 31, 2023
Dec. 31, 2022
 [1]
Shareholders’ Equity [Line Items]          
Ordinary shares, shares authorized 500,000,000 500,000,000      
Ordinary shares, par value $ 0.0001 $ 0.0001      
Common stock, voting rights one        
Ordinary shares, shares issued 4,416,075 4,416,075      
Ordinary shares, shares outstanding 4,416,075 4,416,075   4,416,075  
Subject to possible redemption 14,950,000 14,950,000      
Ordinary share of exercise price     $ 11.5    
Warrants term 5 years        
Redemption price of warrants or rights $ 0.01        
Ordinary per share equals or exceeds $ 16.5        
Percentage of exercise price warrants 115.00%        
Redemption trigger price $ 16.5        
Percentage of market value 165.00%        
Founder Shares [Member]          
Shareholders’ Equity [Line Items]          
Issued and outstanding shares after the initial public offering 20.00%        
Warrant [Member]          
Shareholders’ Equity [Line Items]          
Ordinary share of exercise price $ 11.5        
Effective issue price per share $ 9.35        
Aggregate gross proceeds percentage 60.00%        
Price threshold fair market value of exercise of warrants $ 9.35        
Common Stock [Member]          
Shareholders’ Equity [Line Items]          
Ordinary shares, shares outstanding 4,416,075 4,416,075   3,737,500 [1] 3,737,500
IPO [Member] | Common Stock [Member]          
Shareholders’ Equity [Line Items]          
Subject to possible redemption 14,950,000 14,950,000      
[1] Includes up to an aggregate of 487,500 ordinary shares subject to forfeiture to the extent that the underwriters’ over-allotment option is not exercised in full or in part (see Note 5). As a result of the underwriters’ full exercise of their over-allotment option on July 27, 2023, no founder shares are currently subject to forfeiture.